Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.

Optimal timing for an early invasive strategy in patients with non-ST-segment-elevation acute coronary syndrome remains unclear. We evaluated the relationship between time from hospital admission to coronary angiography and outcomes in high-risk patients with non-ST-segment-elevation acute coronary syndrome who underwent angiography within 48 hours of admission.
Data from 10 027 patients enrolled in the Superior Yield of the New Strategy of Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial were analyzed. Patients were grouped by 6-hour intervals of time from hospital admission to coronary angiography. Primary outcomes were 30-day death or myocardial infarction, in-hospital Thrombolysis In Myocardial Infarction (TIMI) and Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) major bleeding, and blood transfusion. Adjusted estimates of event rates were obtained by use of a multivariable methodology that included possible confounders through baseline and accounted for propensity of time to angiography. The landmark method was used to calculate odds ratios and 95% confidence intervals of outcomes for each time period adjusted for baseline and postbaseline clinical events. Overall, 9216 patients (92%) underwent angiography, 6352 (63%) within 48 hours. Unadjusted and adjusted rates of death/myocardial infarction increased with increasing time to angiography. The adjusted odds ratio for death/myocardial infarction in patients receiving angiography in <6 hours was 0.56 (95% confidence interval 0.41 to 0.74), whereas after 30 hours, there was no significant benefit compared with further delayed angiography. Major bleeding and transfusion did not vary significantly across time-to-angiography intervals.
A decrease in the time to coronary angiography was associated with fewer ischemic outcomes and no increase in bleeding. Randomized clinical trials are needed to provide definitive evidence on optimal timing of coronary angiography but are difficult to design and conduct. Ongoing trials should instead clarify whether delaying angiography to administer aggressive upstream antithrombotic therapies is effective in the current setting of non-ST-segment-elevation acute coronary syndrome management.
AuthorsPierluigi Tricoci, Yuliya Lokhnygina, Lisa G Berdan, Steven R Steinhubl, Dietrich C Gulba, Harvey D White, Neal S Kleiman, Philip E Aylward, Anatoly Langer, Robert M Califf, James J Ferguson, Elliott M Antman, L Kristin Newby, Robert A Harrington, Shaun G Goodman, Kenneth W Mahaffey
JournalCirculation (Circulation) Vol. 116 Issue 23 Pg. 2669-77 (Dec 4 2007) ISSN: 1524-4539 [Electronic] United States
PMID18025532 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Enoxaparin
  • Fibrinolytic Agents
  • Streptokinase
  • Tissue Plasminogen Activator
  • Acute Coronary Syndrome (complications, diagnosis, mortality, therapy)
  • Aged
  • Blood Transfusion
  • Coronary Angiography
  • Enoxaparin (administration & dosage, adverse effects)
  • Female
  • Fibrinolytic Agents (administration & dosage, adverse effects)
  • Hemorrhage (diagnosis, etiology, mortality, therapy)
  • Hospital Mortality
  • Hospitalization
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction (diagnosis, etiology, mortality, therapy)
  • Randomized Controlled Trials as Topic
  • Streptokinase (administration & dosage, adverse effects)
  • Thrombolytic Therapy
  • Time Factors
  • Tissue Plasminogen Activator (administration & dosage, adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: